Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57 The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57

PHILADELPHIA, March 09, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development program… [+16659 chars]
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset - FHMnews